|Articles|March 1, 2004
Cohesive agent performs reliably in all stages of surgery
Cataract surgeons who choose sodium hyaluronate 1.2% (StaarVisc II, STAAR Surgical) for their routine cases know they can rely on it from beginning to end to offer all the features they seek in a viscoelastic.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
Alcon raises offer in amended deal to acquire STAAR Surgical
3
Neurotrophic keratitis outcomes improve with early, stage-based care
4
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
5










































.png)


